Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
Highest Quality | For Research Use Only

SS-31

Buy SS-31 Peptide Monaco

SS-31 is a mitochondria-targeted tetrapeptide. Its mechanism of action primarily involves the mitigation of mitochondrial dysfunction, a common factor in many degenerative diseases and age-related conditions.

The peptide selectively targets cardiolipin, an essential phospholipid in the inner mitochondrial membrane, preserving its function and structure. By preventing the formation of reactive oxygen species (ROS), it mitigates oxidative stress and cellular damage. Research suggests SS-31’s diverse benefits extend across heart disease, neurodegenerative disorders, kidney disease, and aging, improving mitochondrial function.

Showing all 3 results

Potential Benefits of SS-31 Peptide

  • Neuroprotection: Research studies suggest SS-31 has shown potential in protecting retinal ganglion cells from degeneration in glaucoma, an eye condition that can lead to blindness [1].
  • Mitochondrial Health: SS-31 works by preserving the health of mitochondria, the powerhouses of cells. Studies indicate it can reduce oxidative damage and promote energy production, which is crucial for overall cell function [2].
  • Cardiovascular Protection: Studies have suggested that SS-31 could reduce heart damage caused by ischemia-reperfusion injury, a condition that occurs when blood supply returns to tissue after a period of lack of oxygen [3].
  • Kidney Protection: Research suggests SS-31 may protect against kidney damage caused by certain drugs or diseases, such as diabetic nephropathy [4] and [5].
  • Promoting Cell Survival: The peptide has been shown in studies to prevent mitochondrial depolarization, reduce cell apoptosis (programmed cell death), increase cell yield, and improve overall cell health [6].
  • Potential Treatment for Age-Related Diseases: SS-31 research has shown promise in combating age-related diseases by targeting cellular powerhouses [7].
  • Improved Cerebrovascular Function: According to studies, SS-31 treatment has been shown to improve cerebrovascular endothelial function and rescue neurovascular coupling responses [8].
  • Reducing Renal Tubular Damage: Research suggests in cases of unilateral ureteral obstruction, SS-31 has shown potential in decreasing renal tubular apoptosis and damage [9].

References

[1] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC4921212/

[2] https://pubmed.ncbi.nlm.nih.gov/34302976/

[3] https://pubmed.ncbi.nlm.nih.gov/29589186/

[4] https://www.auajournals.org/ doi/full/10.1016/j.juro.2017.02.3115

[5] https://pubmed.ncbi.nlm.nih.gov/26719366/

[6] https://pubmed.ncbi.nlm.nih.gov/17151329/

[7] https://pubmed.ncbi.nlm.nih.gov/30381054/

[8] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC5847870/

[9] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC2584902/

ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Peptides website: https://monaco.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.